You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Cost recovery implementation statement, V1.4

Version 1.4 June 2018

26 June 2018

Book pagination

Appendix 1 - Financial performance by industry sector group

1. Prescription medicines

Volumes[5] 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Biological prescription medicines 580 501 486    
Non-biological prescription medicines - higher charge 522 522 493    
Non-biological prescription medicines - lower charge 6,536 5,888 5,640    
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 71.7 68.5 71.2    
Total A 71.7 68.5 71.2    
B: Expenses[6]
Direct 36.9 40.0 41.8    
Indirect 26.3 28.3 29.8    
Total B 63.2 68.4 71.6    
Surplus (deficit) 8.5 0.1 (0.4)    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.


Footnotes

  1. Number of entries on the ARTG subject to the annual charge.
  2. Number of entries on the ARTG subject to the annual charge.

2. Over the counter medicines

Volumes 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Over the counter medicines 2,667 2,441 2,417    
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 6.7 7.8 7.9    
Total A 6.7 7.8 7.9    
B: Expenses
Direct 2.8 3.0 3.1    
Indirect 2.3 2.6 2.6    
Total B 5.1 5.7 5.8    
Surplus (deficit) 1.6 2.2 2.1    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.

3. Complementary medicines

Volumes 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Registered complementary medicines 132 131 133    
Listed complementary medicines 11,003 10,052 10,238    
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 15.7 13.8 14.3    
Total A 15.7 13.8 14.3    
B: Expenses
Direct 7.2 7.3 8.1    
Indirect 5.2 5.6 5.9    
Total B 12.4 12.9 14.0    
Surplus (deficit) 3.3 0.9 0.3    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.

4. Medical devices, including in-vitro diagnostic (IVD) devices

Volumes 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Included medical devices 44,878 45,267 45,471    
IVD medical devices N/A N/A 2,492    
Other therapeutic goods 359 294 279    
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 34.3 37.2 36.8    
Total A 34.3 37.2 36.8    
B: Expenses
Direct 17.1 19.6 19.4    
Indirect 12.2 13.8 13.8    
Total B 29.4 33.3 33.3    
Surplus (deficit) 4.9 3.9 3.5    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.

5. Good manufacturing practices

Volumes 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Low level GMP licence 105 112 111    
High level GMP licence 163 163 161    
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 11.2 9.9 10.5    
Total A 11.2 9.9 10.5    
B: Expenses
Direct 7.8 8.7 8.8    
Indirect 5.4 5.7 6.1    
Total B 13.2 14.4 14.9    
Surplus (deficit) (2.0) (4.4) (4.4)    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.

6. Blood, blood components and biologicals

Volumes 2015-16
Actual
2016-17
Actual
2017-18
Budget
2018-19
Estimate
2019-20
Estimate
Blood primary site 5 5 5    
Blood secondary site 79 81 75    
Single step manufacturer of human tissue 24 18 17    
Class 2 biological products 20 20 19    
Class 3 biological products 5 6 6    
Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Cost recovery revenue 2.2 2.6 2.5    
Total A 2.2 2.6 2.5    
B: Expenses
Direct 1.6 2.0 1.8    
Indirect 1.3 1.6 1.4    
Total B 2.9 3.6 3.2    
Surplus (deficit) (0.6) (0.9) (0.7)    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.

7. Other activities (such as laboratory, medicines and chemical scheduling etc.)

Revenue and expenses 2015-16
Actual
$'m
2016-17
Actual
$'m
2017-18
Budget
$'m
2018-19
Estimate
$'m
2019-20
Estimate
$'m
A: Revenue
Revenue 2.0 1.7 1.7    
Total A 2.0 1.7 1.7    
B: Expenses
Other Expense 2.0 2.7 2.0    
MMDR Expense N/A 6.9 3.6    
Total B 2.0 8.6 5.6    
Surplus (deficit) 0.0 (6.9) (4.0)    

Note: The financial information in above tables for 2018-19 and 2019-20 will be updated following finalisation of financial information by the Department in July/August 2018.

Book pagination